Chemical Structure : ZLC853
Catalog No.: PC-28745Not For Human Use, Lab Use Only.
ZLC853 is a potent, selective, and orally bioavailable covalent inhibitor of CDK12/13 with IC50 of 40.0 nM and 18.2 nM respectively, inhibits VCaP cell proliferation with IC50 of 13.7 nM.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
ZLC853 is a potent, selective, and orally bioavailable covalent inhibitor of CDK12/13 with IC50 of 40.0 nM and 18.2 nM respectively, inhibits VCaP cell proliferation with IC50 of 13.7 nM.
ZLC853 covalently binds and modifies Cys 1039 in CDK12 and Cys 1017 in CDK13.
ZLC853 exhibits high kinase selectivity for CDK12 and CDK13, shows 16- and 36-fold selectivity over other CDKs with exception of CDK7 (IC50=81.75 nM).
ZLC853 does not engage CDK7 covalently in cells.
ZLC853 (100 nM) inhibits Ser 2 phosphorylation of RNA polymerase II, suppresses transcription of DDR genes, and induces apoptosis in VCaP cells.
ZLC853 (5 and 10 mg/kg, p.o., q.d.) inhibits prostate cancer growth in VCaP CRPC mouse model.
| M.Wt | 697.84 | |
| Formula | C38H45F2N9O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Zhou K, et al. Acta Pharm Sin B. 2026 Nov;16(11):7554-7572.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright